30 closest matches · ranked by relevance
Breast Cancer
Primary: LVEF Results — -8; -6 LVEF Percentage (%)
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
Solid Tumors
Primary: Change in QTcF (QT Corrected According to Fridericia's Formula) — 3.32; 1.76; 1.84; 1.32 ms (Milliseconds)
Breast Cancer
Primary: Maximum Change in LVEF at 3 Months — 1; -5 change in percent ejection fraction
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Cardiotoxicity · Risk Factor, Cardiovascular · Toxicity Due to Chemotherapy
Primary: Left Ventricular Ejection Fraction (LVEF) — 61.1; 59.0; 61.9; 58.4 percent
Acute Myeloid Leukemia (AML) · Acute Lymphoblastic Leukemia (ALL) · Myelodysplastic Syndrome (MDS)
Primary: Effect of CPX-351 on Cardiac Ventricular Repolarization (QTcF) — 0.6; -1.2; 4.3; 5.3 msecs
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
Heart Failure
Primary: The Percentage of Individuals in Each Group With a Significant Decline in the LVEF. — 22; 9 Participants
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Parkinson's Disease
Primary: Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI at Time of Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day)…
Breast Cancer
Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
Pregnancy Complications
Primary: Plasma Concentration Troponin I — 1.2; 1.2 ng/L — p=0.05
Breast Cancer
Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation
Healthy
Primary: Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis — -0.21; -0.31; 0.07; -0.64 ms
Cardiac Toxicity · Chemotherapeutic Agent Toxicity · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Time to All-Cause Mortality: Cohort A — 58.7; 35.8 Months — p=0.0001
Atrial Flutter
Primary: LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation)) — 11; 43; 55; 50 ms
Breast Cancer
Primary: Pre-operative Concentration of NT-proBNP — 38.9; 32.2 pg/ml — p=0.714
Healthy
Primary: Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point — 7.0; 13.0; 12.6 msec — p=<0.001
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 24-Hour Mean Heart Rate Post-dose — -0.19; -1.84; 0.40; -0.09 bpm
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Heart Failure · Cancer Treatment Induced Left Ventricular Dysfunction
Primary: Determine the Percentage of Cancer Survivors That Maintain Left Ventricular Ejection Fraction (LVEF) ≥50% After Discontinuing Cardiac Medications: Beta Blockers…
Cardiac Toxicity · Malignant Neoplasm · Breast Cancer
Primary: Number of Participants Completing the Trial (Exercise Capacity Addendum) — 17; 8 Participants